Ionis Q1 revenue $119M, loss $150M; WAINUA launch delivers $1M royalty; olezarsen NDA filed for FCS

IONIS PHARMACEUTICALS INC

2024-Q1 EPS reported -$0.98 revenue$119,497,000

Q1 total revenue $119M, down 9% YoY from $131M; GAAP operating loss $150M vs $114M prior year.
SPINRAZA royalties $38M (down from $50M); WAINUA contributed $1M royalty in first partial quarter of launch.
Cash and short-term investments $2.2B; 2024 financial guidance reaffirmed.
Olezarsen NDA submitted to FDA for FCS; positive Phase 3 donidalorsen data for HAE, preparing regulatory submissions.
Pipeline progress: eplontersen fast track for ATTR cardiomyopathy, bepirovirsen fast track for CHB, ION224 positive Phase 2 for MASH.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IONIS PHARMACEUTICALS INC updated its first quarter ended March 31, 2024 guidance (reaffirmed).

Period: first quarter ended March 31, 2024
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 7, 2024, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

IONIS PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001140361-24-024648

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.